Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

Ryan Haumschild, PharmD, MS, MBA: One thing that was mentioned earlier was comorbidities with generalized pustular psoriasis [GPP]. Dr Farberg, can you describe some of the comorbidities you commonly ...

Typically, psoriasis—a chronic, inflammatory skin condition—shows up as red patches that have a silver, scaly appearance. Pustular psoriasis is a little different, and can actually be quite serious.

Please provide your email address to receive an email when new articles are posted on . BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Spesolimab exhibited rapid control of ...

Pustular psoriasis is characterized by clearly defined, raised pus-filled blisters, that cover large swatches of skin and is sometimes accompanied by fever, chills and severe itching. This form of ...

Many patients with generalized pustular psoriasis (GPP) flares got no specific treatment for them, despite their high risk of severe complications, according to the biggest study of these episodes to ...

The report highlights opportunities for investment and strategic planning in Pustular Psoriasis clinical trials by offering insights into global trial landscapes, key locations, and trends. It aids in ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...